Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy : A prospective study

Show full item record



Permalink

http://hdl.handle.net/10138/203404

Citation

Joensuu , H , Eriksson , M , Collan , J , Balk , M H , Leyvraz , S & Montemurro , M 2015 , ' Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy : A prospective study ' , Radiotherapy and Oncology , vol. 116 , no. 2 , pp. 233-238 . https://doi.org/10.1016/j.radonc.2015.07.025

Title: Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy : A prospective study
Author: Joensuu, Heikki; Eriksson, Mikael; Collan, Juhani; Balk, Marja H.; Leyvraz, Serge; Montemurro, Michael
Contributor: University of Helsinki, Clinicum
University of Helsinki, Department of Oncology
University of Helsinki, Department of Diagnostics and Therapeutics
Date: 2015-08
Language: eng
Number of pages: 6
Belongs to series: Radiotherapy and Oncology
ISSN: 0167-8140
URI: http://hdl.handle.net/10138/203404
Abstract: Purpose: Gastrointestinal stromal tumor (GIST) has been considered radiation-resistant, and radiotherapy is recommended only for palliation of bone metastases in current treatment guidelines. No registered prospective trial has evaluated GIST responsiveness to radiotherapy. Patients and methods: Patients with GIST progressing at intra-abdominal sites or the liver were entered to this prospective Phase II multicenter study (identifier NCT00515931). Metastases were treated with external beam radiotherapy using either conformal 3D planning or intensity modulated radiotherapy and conventional fractionation to a cumulative planning target volume dose of approximately 40 Gy. Systemic therapy was maintained unaltered during the study. Results: Of the 25 patients entered, 19 were on concomitant tyrosine kinase inhibitor therapy, most often imatinib. Two (8%) patients achieved partial remission, 20 (80%) had stable target lesion size for >= 3 months after radiotherapy with a median duration of stabilization of 16 months, and 3 (12%) progressed. The median time to radiotherapy target lesion progression was 4-fold longer than the median time to GIST progression at any site (16 versus 4 months). Radiotherapy was generally well tolerated. Conclusions: Responses to radiotherapy were infrequent, but most patients had durable stabilization of the target lesions. GIST patients with soft tissue metastases benefit frequently from radiotherapy. (C) 2015 The Authors. Published by Elsevier Ireland Ltd.
Subject: Gastrointestinal stromal tumor (GIST)
Radiotherapy
Imatinib
Sunitinib
GASTROINTESTINAL STROMAL TUMORS
RADIATION-THERAPY
SUNITINIB
CARCINOMA
IMATINIB
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0167814015003795_main.pdf 481.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record